0000904454-21-000630.txt : 20210818 0000904454-21-000630.hdr.sgml : 20210818 20210818192942 ACCESSION NUMBER: 0000904454-21-000630 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210816 FILED AS OF DATE: 20210818 DATE AS OF CHANGE: 20210818 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Loh Evan CENTRAL INDEX KEY: 0001622680 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36066 FILM NUMBER: 211187993 MAIL ADDRESS: STREET 1: 75 KNEELAND STREET CITY: BOSTON STATE: MA ZIP: 02111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001178711 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330960223 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (617) 807-6600 MAIL ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc DATE OF NAME CHANGE: 20090130 FORMER COMPANY: FORMER CONFORMED NAME: NOVACEA INC DATE OF NAME CHANGE: 20020724 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2021-08-16 0001178711 Paratek Pharmaceuticals, Inc. PRTK 0001622680 Loh Evan C/O PARATEK PHARMACEUTICALS, INC. 75 PARK PLAZA, 4TH FLOOR BOSTON MA 02116 1 1 0 0 CEO Common Stock 2021-08-16 4 A 0 75000 0 A 1034291 D Common Stock 2021-08-17 4 S 0 33931 5.12 D 1000360 D Represents performance-based restricted stock units ("PRSUs") granted on July 31, 2019 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 16, 2021. Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $5.02 to $5.22. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. /s/ William M. Haskel, Attorney-in-Fact for Evan Loh 2021-08-18